Jolanda Howe - 30 Jun 2023 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
30 Jun 2023
Net transactions value
-$23,467
Form type
4
Filing time
05 Jul 2023, 19:33:03 UTC
Previous filing
09 May 2023
Next filing
28 Aug 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise +1,563 +88% 3,332 30 Jun 2023 Direct F1
transaction MIRM Common Stock Options Exercise +1,042 +31% 4,374 01 Jul 2023 Direct F1
transaction MIRM Common Stock Sale $23,467 -915 -21% $25.65 3,459 03 Jul 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Performance Restricted Stock Units Options Exercise $0 -1,563 -100% $0.000000* 0 30 Jun 2023 Common Stock 1,563 Direct F1, F3
transaction MIRM Restricted Stock Units Options Exercise $0 -1,042 -33% $0.000000 2,083 01 Jul 2023 Common Stock 1,042 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
F2 Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F3 On March 9, 2021, the reporting person was granted performance-based restricted stock units ("PSUs"), which vest upon the satisfaction of certain performance criteria. On September 29, 2021, such performance criteria were met. 1,562 shares subject to the PSUs vested on September 29, 2021, and 1,563 shares vested on June 30, 2023.
F4 The restricted stock units vest in a series of three successive equal annual installments beginning July 1, 2023.